Table 3. Antimicrobial susceptibilities of the most common isolates including the ESBL-producing ones, from intra-abdominal infections and urinary-tract infections, from SMART study in Mexico from 2009 to 2015.

Pathogen	% Susceptibility
	ETP	IMP	TZP	SAM	FOX	CAZ	CRO	CTX	FEP	LVX	CIP	AMK
Escherichia coli	99	99	87	22	79	50	45	45	48	37	36	97
Escherichia coli, ESBL	99	99	81	6	72	9	1	1	1	11	11	94
Escherichia coli, non ESBL	100	99	92	37	85	90	90	90	96	62	60	99
Klebsiella pneumoniae	97	98	85	47	88	62	56	57	60	80	64	96
Klebsiella pneumoniae, ESBL	98	100	70	7	87	13	0	1	7	64	27	93
Klebsiella pneumoniae, non ESBL	97	96	94	77	89	95	92	94	97	93	90	98
Pseudomonas aeruginosa	0	62	60	0	0	59	0	0	61	58	59	70
Acinetobacter baumannii	0	23	11	25	0	11	6	7	9	9	6	19
Enterobacter cloacae	84	98	67	25	5	55	51	52	67	89	85	93
Proteus mirabilis	100	34	98	76	98	98	92	96	94	89	72	100
Proteus mirabilis, ESBL	100	0	100	50	100	50	0	0	50	50	0	100
Proteus mirabilis, non ESBL	100	35	98	76	98	100	94	98	96	90	74	100
Klebsiella oxytoca	100	96	90	57	93	82	75	77	82	74	73	100
Klebsiella oxytoca, ESBL	100	100	69	0	85	23	0	0	8	23	15	100
Klebsiella oxytoca, non ESBL	100	95	96	71	94	97	94	97	99	87	87	100

ETP: ertapenem, IMP: imipenem, TZP: Piperacillin-Tazobactam, SAM: Ampicillin-Sulbactam, FOX: cefoxitin, CAZ: ceftazidime, CRO: ceftriaxone, CTX: cefotaxime, FEP: cefepime, LVX: levofloxacin, CIP: ciprofloxacin and AMK: amikacin. These MIC breakpoints have not been defined by the Clinical and Laboratory Standards Institute.